Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 62-76 http://medscipublisher.com/index.php/cge 75 Orsini A., Mastracci L., Bozzarelli I., Ferrari A., Isidori F., Fiocca R., Lugaresi M., D’Errico A., Malvi D., Cataldi-Stagetti E., Spaggiari P., Tomezzoli A., Albarello L., Ristimäki A., Bottiglieri L., Krishnadath K., Rosati R., Romario U., Manzoni G., Räsänen J., Martinelli G., Mattioli S., Bonora E., and Consortium O., 2023, Correlations between molecular alterations histopathological characteristics and poor prognosis in esophageal adenocarcinoma, Cancers, 15(5): 1408. https://doi.org/10.3390/cancers15051408 Pectasides E., 2016, Genomic alterations and targeted therapy in gastric and esophageal adenocarcinoma, Clinical Therapeutics, 38(7): 1589-1599. https://doi.org/10.1016/j.clinthera.2016.03.016 Pectasides E., Stachler M., Derks S., Liu Y., Maron S., Islam M., Alpert L., Kwak H., Kindler H., Polite B., Sharma M., Allen K., O’Day E., Lomnicki S., Maranto M., Kanteti R., Fitzpatrick C., Weber C., Setia N., Xiao S., Hart J., Nagy R., Kim K., Choi M., Min B., Nason K., O'Keefe L., Watanabe M., Baba H., Lanman R., Agoston A., Oh D., Dunford A., Thorner A., Ducar M., Wollison B., Coleman H., Ji Y., Posner M., Roggin K., Turaga K., Chang P., Hogarth K., Siddiqui U., Gelrud A., Ha G., Freeman S., Rhoades J., Reed S., Gydush G., Rotem D., Davison J., Imamura Y., Adalsteinsson V., Lee J., Bass A., and Catenacci D., 2018, Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma, Cancer Discovery, 8(1): 37-48. https://doi.org/10.1158/2159-8290.CD-17-0395 Peng D.F., Guo Y., Chen H., Zhao S., Washington K., Hu T., Shyr Y., and El-Rifai W., 2017, Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas, Scientific Reports, 7(1): 40729. https://doi.org/10.1038/srep40729 Peng W., Tu G., Zhao Z., He B., Cai Q., Zhang P., Peng X., Shi S., and Wang X., 2021, DNA methylome and transcriptome analysis established a model of four differentially methylated positions (DMPs) as a diagnostic marker in esophageal adenocarcinoma early detection, PeerJ, 9: e11355. https://doi.org/10.7717/peerj.11355 Sahgal P., Huffman B.M., Patil D.T., Chatila W.K., Yaeger R., Cleary J.M., and Sethi N.S., 2021, Early TP53 alterations shape gastric and esophageal cancer development, Cancers, 13(23): 5915. https://doi.org/10.3390/cancers13235915 Salem M., Puccini A., Xiu J., Raghavan D., Lenz H., Korn W., Shields A., Philip P., Marshall J., and Goldberg R., 2018, Comparative molecular analyses of esophageal squamous cell carcinoma esophageal adenocarcinoma and gastric adenocarcinoma, The Oncologist, 23(11): 1319-1327. https://doi.org/10.1634/theoncologist.2018-0143 Schoemmel M., Loeser H., Kraemer M., Wagener-Ryczek S., Hillmer A., Bruns C., Thelen M., Schröder W., Zander T., Lechner A., Buettner R., Schlößer H., Gebauer F., Quaas A., Quaas H., Loeser H., and Quaas A., 2021, Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus, Clinical and Translational Oncology, 23: 1601-1610. https://doi.org/10.1007/s12094-021-02556-2 Sihag S., Nussenzweig S.C., Walch H.S., Hsu M., Tan K., Torre S., Janjigian Y., Maron S., Ku G., Tang L., Shah P., Wu A., Jones D., Solit D., Schultz N., Ganesh K., Berger M., and Molena D., 2022, The role of the TP53 pathway in predicting response to neoadjuvant therapy in esophageal adenocarcinoma, Clinical Cancer Research, 28(12): 2669-2678. https://doi.org/10.1158/1078-0432.CCR-21-4016 Slabý O., Srovnal J., Radová L., Gregar J., Juracek J., Lužná P., Svoboda M., Hajdůch M., and Ehrmann J., 2015, Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma, Carcinogenesis, 36(5): 521-527. https://doi.org/10.1093/carcin/bgv023 Souza R., 2018, Esophageal adenocarcinomas: a need for speed driven by immune pathways that have druggable targets, Cellular and Molecular Gastroenterology and Hepatology, 5: 652-653. https://doi.org/10.1016/j.jcmgh.2018.01.020 Stachler M.D., Bao C., Tourdot R.W., Brunette G.J., Stewart C., Sun L., Baba H., Watanabe M., Agoston A., Jajoo K., Davison J., Nason K., Getz G., Wang K., Imamura Y., Odze R., Bass A., and Zhang C., 2023, Genomic signatures of past and present chromosomal instability in the evolution of barrett’s esophagus to esophageal adenocarcinoma, bioRxiv, 2023: 437288. https://doi.org/10.1101/2021.03.26.437288 Stachler M., Camarda N., Deitrick C., Kim A., Agoston A., Odze R., Hornick J., Nag A., Thorner A., Ducar M., Noffsinger A., Lash R., Redston M., Carter S., Davison J., and Bass A., 2018, Detection of mutations in barrett's esophagus before progression to high-grade dysplasia or adenocarcinoma, Gastroenterology, 155(1): 156-167. https://doi.org/10.1053/j.gastro.2018.03.047 Sundaram S., Kim E., Jones G., Sivagnanam S., Tripathi M., Miremadi A., Pietro M., Coussens L., Fitzgerald R., Chang Y., and Zhuang L., 2022, Deciphering the immune complexity in esophageal adenocarcinoma and pre-cancerous lesions with sequential multiplex immunohistochemistry and sparse subspace clustering approach, Frontiers in Immunology, 13: 874255. https://doi.org/10.3389/fimmu.2022.874255 Wagener-Ryczek S., Schoemmel M., Kraemer M., Bruns C., Schroeder W., Zander T., Gebauer F., Alakus H., Merkelbach-Bruse S., Buettner R., Loeser H., Thelen M., Schlößer H., and Quaas A., 2020, Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma, Cancer Immunology Immunotherapy, 69: 523-533. https://doi.org/10.1007/s00262-019-02475-w
RkJQdWJsaXNoZXIy MjQ4ODYzNA==